These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27571900)

  • 21. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.
    Hensley LE; Stevens EL; Yan SB; Geisbert JB; Macias WL; Larsen T; Daddario-DiCaprio KM; Cassell GH; Jahrling PB; Geisbert TW
    J Infect Dis; 2007 Nov; 196 Suppl 2():S390-9. PubMed ID: 17940975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).
    Morikawa S; Saijo M; Kurane I
    Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):391-8. PubMed ID: 17610952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus.
    Mire CE; Geisbert JB; Agans KN; Deer DJ; Fenton KA; Geisbert TW
    J Infect Dis; 2016 Oct; 214(suppl 3):S263-S267. PubMed ID: 27284090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.
    Günther S; Feldmann H; Geisbert TW; Hensley LE; Rollin PE; Nichol ST; Ströher U; Artsob H; Peters CJ; Ksiazek TG; Becker S; ter Meulen J; Olschläger S; Schmidt-Chanasit J; Sudeck H; Burchard GD; Schmiedel S
    J Infect Dis; 2011 Nov; 204 Suppl 3():S785-90. PubMed ID: 21987751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology.
    Reed DS; Lackemeyer MG; Garza NL; Sullivan LJ; Nichols DK
    Microbes Infect; 2011 Oct; 13(11):930-6. PubMed ID: 21651988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates.
    Reisler RB; Yu C; Donofrio MJ; Warren TK; Wells JB; Stuthman KS; Garza NL; Vantongeren SA; Donnelly GC; Kane CD; Kortepeter MG; Bavari S; Cardile AP
    Emerg Infect Dis; 2017 Aug; 23(8):1316-1324. PubMed ID: 28726603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.
    Geisbert TW; Hensley LE; Jahrling PB; Larsen T; Geisbert JB; Paragas J; Young HA; Fredeking TM; Rote WE; Vlasuk GP
    Lancet; 2003 Dec; 362(9400):1953-8. PubMed ID: 14683653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
    Wong G; Richardson JS; Pillet S; Racine T; Patel A; Soule G; Ennis J; Turner J; Qiu X; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S379-83. PubMed ID: 25957963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
    Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
    Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ebola virus convalescent blood products: where we are now and where we may need to go.
    Burnouf T; Seghatchian J
    Transfus Apher Sci; 2014 Oct; 51(2):120-5. PubMed ID: 25457751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
    Gupta M; Mahanty S; Bray M; Ahmed R; Rollin PE
    J Virol; 2001 May; 75(10):4649-54. PubMed ID: 11312335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies.
    Geisen C; Kann G; Strecker T; Wolf T; Schüttfort G; van Kraaij M; MacLennan S; Rummler S; Weinigel C; Eickmann M; Fehling SK; Krähling V; Seidl C; Seifried E; Schmidt M; Schäfer R
    Vox Sang; 2016 May; 110(4):329-35. PubMed ID: 26766162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus.
    Qiu X; Audet J; Lv M; He S; Wong G; Wei H; Luo L; Fernando L; Kroeker A; Fausther Bovendo H; Bello A; Li F; Ye P; Jacobs M; Ippolito G; Saphire EO; Bi S; Shen B; Gao GF; Zeitlin L; Feng J; Zhang B; Kobinger GP
    Sci Transl Med; 2016 Mar; 8(329):329ra33. PubMed ID: 26962157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recently Identified Mutations in the Ebola Virus-Makona Genome Do Not Alter Pathogenicity in Animal Models.
    Marzi A; Chadinah S; Haddock E; Feldmann F; Arndt N; Martellaro C; Scott DP; Hanley PW; Nyenswah TG; Sow S; Massaquoi M; Feldmann H
    Cell Rep; 2018 May; 23(6):1806-1816. PubMed ID: 29742435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Convalescent plasma: new evidence for an old therapeutic tool?
    Marano G; Vaglio S; Pupella S; Facco G; Catalano L; Liumbruno GM; Grazzini G
    Blood Transfus; 2016 Mar; 14(2):152-7. PubMed ID: 26674811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful topical respiratory tract immunization of primates against Ebola virus.
    Bukreyev A; Rollin PE; Tate MK; Yang L; Zaki SR; Shieh WJ; Murphy BR; Collins PL; Sanchez A
    J Virol; 2007 Jun; 81(12):6379-88. PubMed ID: 17428868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
    Agnandji ST; Huttner A; Zinser ME; Njuguna P; Dahlke C; Fernandes JF; Yerly S; Dayer JA; Kraehling V; Kasonta R; Adegnika AA; Altfeld M; Auderset F; Bache EB; Biedenkopf N; Borregaard S; Brosnahan JS; Burrow R; Combescure C; Desmeules J; Eickmann M; Fehling SK; Finckh A; Goncalves AR; Grobusch MP; Hooper J; Jambrecina A; Kabwende AL; Kaya G; Kimani D; Lell B; Lemaître B; Lohse AW; Massinga-Loembe M; Matthey A; Mordmüller B; Nolting A; Ogwang C; Ramharter M; Schmidt-Chanasit J; Schmiedel S; Silvera P; Stahl FR; Staines HM; Strecker T; Stubbe HC; Tsofa B; Zaki S; Fast P; Moorthy V; Kaiser L; Krishna S; Becker S; Kieny MP; Bejon P; Kremsner PG; Addo MM; Siegrist CA
    N Engl J Med; 2016 Apr; 374(17):1647-60. PubMed ID: 25830326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X; Yao C; Wei Y; Kou Z; Hu K
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Key Infectivity Parameters in the Transmission of Ebola Virus Makona in Macaques.
    de La Vega MA; Wong G; Wei H; He S; Bello A; Fausther-Bovendo H; Audet J; Tierney K; Tran K; Soule G; Racine T; Strong JE; Qiu X; Kobinger GP
    J Infect Dis; 2022 Sep; 226(4):616-624. PubMed ID: 34626109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.